Paper Review Records
All Paper Review Records
11 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
Caregiver-reported developmental regression in Coffin-Lowry syndrome
Lilia Kazerooni; Panteha Hayati Rezvan; Maeve C. Lucas; Samuel T. Otey; Stella V. Gray; Mariam M Yousuf; Madeline A. Oswald; Mackenzie Silverman; Abhik K. Banerjee; Devin A. King; Jonathan D. SantoroShow moreShow less
1. Children's Hospital Los Angeles; 2. University of Southern CaliforniaShow moreShow less
Long-term follow-up of a randomized controlled trial of choline for neurodevelopment in fetal alcohol spectrum disorder: corpus callosum white matter microstructure and neurocognitive outcomes
Blake A. Gimbel; Mary E. Anthony; Abigail M. Ernst; Donovan J. Roediger; Erik de Water; Judith K. Eckerle; Christopher J. Boys; Joshua P. Radke; Bryon A. Mueller; Anita J. Fuglestad; Steven H. Zeisel; Michael K. Georgieff; Jeffrey R. WozniakShow moreShow less
1. University of Minnesota Twin Cities, Minneapolis, USA; 2. Great Lakes Neurobehavioral Center, Edina, USA; 3. Fagron, Inc., Saint Paul, USA; 4. University of North Florida, Jacksonville, USA; 5. University of North Carolina, Chapel Hill, USAShow moreShow less
Social attention during object engagement: toward a cross-species measure of preferential social orienting
Claire Weichselbaum; Nicole Hendrix; Jordan Albright; Joseph D. Dougherty; Kelly N. Botteron; John N. Constantino; Natasha MarrusShow moreShow less
1. Department of Psychiatry, Washington University School of Medicine, St Louis, USA; 2. Department of Genetics, Washington University School of Medicine, St Louis, USA; 3. Department of Pediatrics, Marcus Autism Center, Emory University Pediatric Institute, Atlanta, USA; 4. Virginia Tech Autism Clinic & Center for Autism Research, Virginia Polytechnic Institute and State University, Blacksburg, USA; 5. Department of Radiology, Washington University School of Medicine, St Louis, USAShow moreShow less
The feasibility and utility of hair follicle sampling to measure FMRP and FMR1 mRNA in children with or without fragile X syndrome: a pilot study
Isha Jalnapurkar; Jean A. Frazier; Mark Roth; David M. Cochran; Ann Foley; Taylor Merk; Lauren Venuti; Lucienne Ronco; Shane Raines; Diego CadavidShow moreShow less
1. Department of Psychiatry, EK Shriver Center, University of Massachusetts Medical School, Worcester, USA; 2. Fulcrum Therapeutics, Cambridge, USAShow moreShow less
A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)
Elizabeth Berry-Kravis; Randi Hagerman; Dejan Budimirovic; Craig Erickson; Helen Heussler; Nicole Tartaglia; Jonathan Cohen; Flora Tassone; Thomas Dobbins; Elizabeth Merikle; Terri Sebree; Nancy Tich; Joseph M. Palumbo; Stephen O’QuinnShow moreShow less
1. Departments of Pediatrics and Neurological Sciences, Rush University Medical Center, Chicago, USA; 2. Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California-Davis Medical Center, Sacramento, USA; 3. Department of Pediatrics, University of California Davis School of Medicine, Sacramento, USA; 4. Departments of Psychiatry and Child Psychiatry, Fragile X Clinic, Kennedy Krieger Institute/the Johns Hopkins Medical Institutions, Baltimore, USA; 5. Department of Psychiatry & Behavioral Sciences-Child Psychiatry, Johns Hopkins School of Medicine, Baltimore, USA; 6. Department of Psychiatry and Behavioral Neuroscience, Cincinnati Children’s Hospital Medical Center and the University of Cincinnati College of Medicine, Cincinnati, USA; 7. Centre for Clinical Trials in Rare Neurodevelopmental Disorders, Children’s Health Queensland, Brisbane, Australia; 8. Centre for Child Health Research, University of Queensland, Brisbane, Australia; 9. Department of Pediatrics, Developmental Pediatrics, University of Colorado School of Medicine, Children’s Hospital Colorado, Aurora, USA; 10. Fragile X Alliance Inc, North Caulfield, VIC, Australia; 11. Centre for Developmental Disability Health Victoria, Monash University, Clayton, Australia; 12. Department of Biochemistry and Molecular Medicine, School of Medicine, University of California-Davis, Sacramento, USA; 13. The Griesser Group, Conshohocken, USA; 14. Labcorp Drug Development, Durham, USA; 15. Zynerba Pharmaceuticals Inc., Devon, USAShow moreShow less
Divergent presentation of anxiety in high-risk groups within the intellectual disability population
Laura Groves; Joanna Moss; Chris Oliver; Rachel Royston; Jane Waite; Hayley CrawfordShow moreShow less
1. School of Psychology, University of Birmingham, Edgbaston, UK; 2. School of Psychology, University of Surrey, Guildford, UK; 3. Division of Psychiatry, University College London, London, UK; 4. School of Health and Life Sciences, Aston University, Birmingham, UK; 5. Mental Health and Wellbeing Unit, Warwick Medical School, University of Warwick, Coventry, UKShow moreShow less
FAQ
How long does Journal of Neurodevelopmental Disorders take to review a manuscript?
As of 2026-11-19, CrushSCI has 11 complete review records for Journal of Neurodevelopmental Disorders. The fastest paper went from submission to acceptance in 159 days (Long-term follow-up of a randomized controlled trial of choline for neurodevelopment in fetal alcohol spectrum disorder: corpus callosum white matter microstructure and neurocognitive outcomes, received 2022-06-30, accepted 2022-12-06); the slowest took 1027 days. The average is 346.8 days and the median is 304 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
